A5042852106- Bone health and osteoporosis research
- Health Systems, Economic Evaluations, Quality of Life
- Pneumonia and Respiratory Infections
- Phagocytosis and Immune Regulation
- Sepsis Diagnosis and Treatment
- Schizophrenia research and treatment
- Bone and Joint Diseases
- Neonatal and Maternal Infections
- Emergency and Acute Care Studies
- Enhanced Recovery After Surgery
- Neuroendocrine Tumor Research Advances
- FOXO transcription factor regulation
- Chronic Disease Management Strategies
- Pancreatic and Hepatic Oncology Research
- Palliative Care and End-of-Life Issues
- Hip and Femur Fractures
- Growth Hormone and Insulin-like Growth Factors
- Pituitary Gland Disorders and Treatments
- Bone health and treatments
- Nosocomial Infections in ICU
- Cancer Diagnosis and Treatment
Hanyang University
2023-2025
Taipei Veterans General Hospital
2010-2017
National Yang Ming Chiao Tung University
2013
<h3>Background</h3> Age-related alterations in the clinical characteristics and performance of severity scoring systems for community-acquired pneumonia (CAP) are unknown. <h3>Methods</h3> Consecutive patients with CAP presenting to emergency department were prospectively studied. Patients classified as younger adults (age 18–64 years), elderly 65–84 years) very old subjects ≥85 years). Clinical characteristics, complications, outcomes validity index (PSI) CURB-65 categories compared across...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with 5-year survival low of 2% in advanced cases. Despite being fatal disease, there lack good predictor prognosis which can aid the management patients. The tumor microenvironment PDAC, including immune cells, plays vital role progression and invasiveness PDAC. Cluster differentiation 47 (CD47) has "don't eat me signal" to macrophages through receptor signal regulatory protein alpha, prevents cell surveillance cancer...
The present study was aimed to investigate glucose homeostasis and insulin secretion in acromegalic patients during octreotide-long acting release (LAR) therapy designed as an observational prospective study. 18 who had undergone trans-sphenoidal surgery with active disease were included. All treated octreotide-LAR injection for 1 year. These received oral tolerance test (OGTT) before, 21 days after, year after treatment. Primary outcomes changes levels OGTT. We also determined the...